Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
•
Oncology
What criteria are used to select patients who have locally advanced BCC patients for treatment with sonidegib?
What treatment combinations be used to maximize results?
Related Questions
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
What are your favorite strategies in fixing post-surgical depressions from facial flaps?
When do you recommend SRT, if ever, for small SCCs and BCCs?
In what clinical scenarios do you consider pre- or post-treatment with Imiquimod for cutaneous melanoma?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
After achieving clinical response to bexarotene for cutaneous lymphoma (e.g., MF stage Ib or FMF), do you wean to the lowest dose for sustained remission, and if so, when?
What patient characteristics or clinical scenarios guide the decision in performing slow Mohs procedures?
What is your experience with itraconazole as a primary or adjunct therapy for individuals with numerous BCCs?
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
How would you manage a large area of multiple, recurrent cutaneous squamous cell carcinomas of the scalp with ulcerations and non-healing areas despite cryotherapy, multiple Mohs procedures, and 5-FU?